Zobrazeno 1 - 10
of 662
pro vyhledávání: '"Epidermal growth factor receptor–tyrosine kinase inhibitors"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Molecular targeted therapy resistance remains a major challenge in treating lung adenocarcinoma (LUAD). The resistance of Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs, epidermal growth factor receptor-tyrosine kinas
Externí odkaz:
https://doaj.org/article/82880fd7d7644e3c8d2b9ace73f79c30
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 4, Pp 283-290 (2024)
Non-small cell lung cancer (NSCLC) is a prevalent tumour type in our country, with lung squamous carcinoma being a commonly observed NSCLC subtype besides lung adenocarcinoma. Epidermal growth factor receptor (EGFR) is a significant driver gene in lu
Externí odkaz:
https://doaj.org/article/b9c23f5643194643905fa14057dbbb17
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation. This retrospective study aimed to profile skin to
Externí odkaz:
https://doaj.org/article/2b2b9bb201e54139a05e3e81b78e11ed
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) are a class of oral targeted anticancer drugs that have been demonstrated to significantly inhibit tumor progression and improve clinical prognosis in patients diagnosed with EGF
Externí odkaz:
https://doaj.org/article/911e9458d0b14294b7aa9ce69ede71bb
Publikováno v:
Zhongguo linchuang yanjiu, Vol 37, Iss 1, Pp 1-5 (2024)
Non-small cell lung cancer (NSCLC) is the main type of lung cancer, accounting for 85% to 90% of cases. The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has greatly improved the prognosis of NSCLC patients. However,
Externí odkaz:
https://doaj.org/article/968e4ae9af654dbb8a759a85addcc98e
Autor:
Sviatoslav Chekhun, Assumpció Lopez-Paradís, Aintzane Urbizu, Teresa Morán, Anabel Mañes, Marc Cucurull, Carlos Martínez-Barenys, Iris Teruel, Gloria Moragas, Enric Carcereny, Ana Maria Muñoz Mármol, Maria Saigí
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 6, Pp 1182-1187 (2023)
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. Nevertheles
Externí odkaz:
https://doaj.org/article/548b16587d6e4b5780c5798654aef425
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 11, Pp 874-880 (2023)
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR are effective in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients, but drug resistance is inevitable. With the application and expansion of indiv
Externí odkaz:
https://doaj.org/article/eb14d81ecb434782a872d100dc8d5b81
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background It remains uncertain whether first-line treatment with upfront brain radiotherapy (RT) in combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is superior to EGFR-TKIs alone for EGFR-mutated non-sm
Externí odkaz:
https://doaj.org/article/c92c65d00fc1473298b6b5cb47f5a541
Autor:
Ting-Wei Wang, Heng-Sheng Chao, Hwa-Yen Chiu, Chia-Feng Lu, Chien-Yi Liao, Yen Lee, Jyun-Ru Chen, Tsu-Hui Shiao, Yuh-Min Chen, Yu-Te Wu
Publikováno v:
Translational Oncology, Vol 39, Iss , Pp 101826- (2024)
Background and objective: Epidermal growth factor receptor (EGFR)–targeted tyrosine kinase inhibitors (TKIs) are the first-line therapy for EGFR-mutant non-small-cell lung cancer (NSCLC). Early prediction of treatment failure in patients with brain
Externí odkaz:
https://doaj.org/article/a3b501ecd13b4b559a353f919b027c01
Publikováno v:
Heliyon, Vol 9, Iss 12, Pp e22591- (2023)
Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with a high incidence and mortality rates of all cancers. Locally advanced or metastatic NSCLC patients can benefit from platinum-based chemotherapy and targeted therapy drugs.
Externí odkaz:
https://doaj.org/article/ae10b2f20e7248c881dab812a9d1d98a